Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

576 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.
Rembeck K, Waldenström J, Hellstrand K, Nilsson S, Nyström K, Martner A, Lindh M, Norkrans G, Westin J, Pedersen C, Färkkilä M, Langeland N, Buhl MR, Mørch K, Christensen PB, Lagging M. Rembeck K, et al. Among authors: farkkila m. Hepatology. 2014 Jun;59(6):2131-9. doi: 10.1002/hep.27009. Epub 2014 Apr 25. Hepatology. 2014. PMID: 24519039 Clinical Trial.
Hepatitis C treatment response kinetics and impact of baseline predictors.
Lindh M, Arnholm B, Eilard A, Färkkilä M, Hellstrand K, Lagging M, Langeland N, Mørch K, Nilsson S, Pedersen C, Buhl MR, Wahlberg T, Wejstål R, Westin J, Norkrans G. Lindh M, et al. Among authors: farkkila m. J Viral Hepat. 2011 Jun;18(6):400-7. doi: 10.1111/j.1365-2893.2010.01323.x. J Viral Hepat. 2011. PMID: 20500548
Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.
Alsiö A, Jannesson A, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Westin J, Hellstrand K, Norkrans G, Lagging M; NORDynamIC Study Group. Alsiö A, et al. Among authors: farkkila m. Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1631-5. doi: 10.1007/s10096-011-1486-5. Epub 2011 Nov 24. Eur J Clin Microbiol Infect Dis. 2012. PMID: 22113307
Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.
Waldenström J, Färkkilä M, Rembeck K, Norkrans G, Langeland N, Mørch K, Pedersen C, Rauning Buhl M, Nieminen U, Nuutinen H, Alsiö Å, Holmström L, Jungnelius R, Lund K, Rubensson A, Torell E, Westin J, Lagging M. Waldenström J, et al. Among authors: farkkila m. Scand J Gastroenterol. 2016 Mar;51(3):337-43. doi: 10.3109/00365521.2015.1087588. Epub 2015 Sep 29. Scand J Gastroenterol. 2016. PMID: 26418670 Free PMC article. Clinical Trial.
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection.
Waldenström J, Westin J, Nyström K, Christensen P, Dalgard O, Färkkilä M, Lindahl K, Nilsson S, Norkrans G, Krarup H, Norrgren H, Rauning Buhl M, Stenmark S, Lagging M. Waldenström J, et al. Among authors: farkkila m. PLoS One. 2016 May 11;11(5):e0155142. doi: 10.1371/journal.pone.0155142. eCollection 2016. PLoS One. 2016. PMID: 27167219 Free PMC article. Clinical Trial.
Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Christensen P, Leutscher P, Norkrans G; NORDynamIC Study Group. Lagging M, et al. Among authors: farkkila m. Hepatology. 2008 Aug;48(2):695. doi: 10.1002/hep.22450. Hepatology. 2008. PMID: 18666232 No abstract available.
576 results